 Download this press release as a PDF document.
Pittsburgh, PA--(HISPANIC PR WIRE)--March 20, 2007--GlaxoSmithKline [NYSE: GSK] Consumer Healthcare announces today that the U.S. Food and Drug Administration (FDA) approved the weight-loss product orlistat 60 mg capsules for over-the-counter (OTC) use in the United States. GSK Consumer Healthcare will market OTC orlistat under the brand name alli(TM) (pronounced Alai). Approved for use by overweight adults in conjunction with a reduced-calorie, low-fat diet, alli(TM) helps people lose 50 percent more weight than with diet alone. alli(TM) is the only FDA-approved weight-loss product available to consumers without a prescription, and it is the first clinically proven over-the counter product to be combined with a comprehensive support program. alli(TM) is expected to be available in stores nationwide by summer 2007. This approval marks the start of an educational program that includes a series of resources online, and available in Spanish, at mialli.com.
Consumers spend billions of dollars each year on fad diets, unproven miracle pills, and potentially unsafe weight-loss supplements that may not work. alli(TM) is the clinically proven option to these hyped, quick-fix products that mislead overweight adults away from weight-loss strategies that are backed by medical science. With alli(TM), consumers have access to an individually tailored online action plan that provides support and the necessary tools to help them lose 50 percent more weight than with diet alone.
 With alli(TM), consumers have access to an individually tailored online action plan that provides support and the necessary tools to help them lose 50 percent more weight than with diet alone |
“I’m excited about the FDA approval of alli(TM) because it will offer many Hispanic Americans an effective approach to weight loss when used with a reduced-calorie, low-fat diet,” said Sylvia Melendez-Klinger, a registered and licensed dietician and certified fitness trainer. “As you know, overweight and obesity are on the rise in the U.S., especially among Hispanic-Americans. This is concerning because obesity is closely linked to health problems such as diabetes and cardiovascular disease.”
Why alli(TM) is Different
Unlike other products on store shelves, alli(TM) is a proven medicine with a comprehensive support program. To help consumers get off to a successful start, the alli(TM) package will include Welcome and Companion Guides, a Guide to Healthy Eating, a Daily Journal, a Calorie and Fat Counter, Quick Fact Cards, and free access to an individualized online action plan at mialli.com. All materials will be made available in Spanish.
“With alli(TM), we’re excited to offer a revolutionary approach to weight loss,” says Steven L. Burton, Vice President, Weight Control, GlaxoSmithKline. “alli(TM) is more than a pill - it’s a comprehensive program that works in conjunction with a sensible diet to increase weight loss. Because weight loss doesn’t happen overnight, we’re starting to educate consumers now about the importance of realistic expectations, gradual weight loss and lifestyle changes. That’s the way to see results and with alli(TM), we know they can do it.”
Starting today, GSK Consumer Healthcare will gear up production to have the product ready for shipment and in stores by the summer. The company is using this period to build awareness and understanding about the product and its intended user – with the message – alli(TM) is not for everyone. It’s for the committed consumer who can follow a reduced-calorie, low-fat diet. For this consumer, alli(TM) will provide a unique, proven approach to weight loss, offering straight talk, educational tools and an online support program – mialli.com.
How to Use alli(TM)
alli(TM), the only FDA-approved weight-loss medication soon to be available without a prescription, is indicated for weight loss in overweight adults18 years and older when used along with a reduced-calorie, low-fat diet. The recommended dose of alli(TM) is one 60 mg capsule three times a day with meals containing fat.
Taken at meal-time, alli(TM) works by blocking about 25 percent of the fat in the food a person eats. Because of the way it works, alli(TM) must be used in conjunction with a reduced-calorie, low-fat diet containing about 15 grams of fat per meal. The guides and information supplied in the alli(TM) package help the consumer to control the amount of fat in their meals, and to follow an appealing, reduced-calorie, low-fat diet.
Consuming a meal with too much fat while taking alli(TM) can result in bowel changes such as having an urgent need to use the bathroom. These changes, called treatment effects, generally occur in the first weeks of treatment, are not harmful, and can be managed by following the recommended diet with about 15 grams of fat per meal. Users should take a multivitamin once a day, at bedtime, because alli can reduce the absorption of some vitamins.
Safety and Efficacy
alli(TM) (60 mg orlistat capsules) is safe and effective when used as directed. As the most extensively studied weight-loss medication on the market, the safety and efficacy of orlistat is very well established. A higher dose of orlistat has been marketed as the prescription drug Xenical(R) (orlistat 120 mg capsules) in the U.S. since 1999 and is supported by nine years of worldwide use in 145 other countries. Orlistat experience in more than 25 million patient treatments and more than 100 clinical studies with more than 30,000 patients is unprecedented. One of these studies with Xenical is the four-year landmark XENDOS trial conducted by Roche, its inventor and manufacturer.. This study is the longest study ever conducted for a weight-loss medicine.
Xenical (orlistat120 mg capsules) will remain available by prescription for those who should be treated under the care of a physician. Xenical will continue to be manufactured and sold by Roche.
For more information on alli(TM), go to mialli.com.
About Overweight and Obesity
Although people of all ages, races and ethnicity can become overweight or obese, there are some people who are at greater risk than others.(1) Overweight and obesity occur at higher rates in Hispanic Americans and minority women are particularly affected by overweight and obesity.(2) Overweight and obesity are associated with an increased risk of developing health problems such as hypertension, type 2 diabetes and heart disease.(3) Many such obesity-related diseases are found in higher rates among various members of racial-ethnic minorities.(4) Factors that can contribute to overweight include an abundance of high-calorie foods, low levels of physical activity, behavior, environment and genetics.(5) Multiple studies have shown that a modest reduction in weight improves health outcomes significantly in overweight or obese patients.(6),(7)
About GlaxoSmithKline Consumer Healthcare
GSK Consumer Healthcare is one of the world's largest over-the-counter consumer healthcare products companies. Its more than 30 well-known brands include the leading smoking cessation products, Nicorette(R), NicoDerm(R) CQ and Commit(R) as well as many medicine cabinet staples, including Abreva(R), Aquafresh(R), Sensodyne,(R) Tums(R) and Breathe Right(R).
About GlaxoSmithKline
GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit: http://www.gsk.com.
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the Operating and Financial Review and Prospects in the company's Annual Report 2004.
References:
(1) American Obesity Association. “Obesity in Minority Populations.” http://www.obesity.org/subs/fastfacts/Obesity_Minority_Pop.shtml. Accessed 8.01.05.
(2) American Obesity Association. “Obesity in Minority Populations.” http://www.obesity.org/subs/fastfacts/Obesity_Minority_Pop.shtml. Accessed 8.01.05.
(3) Centers for Disease Control and Prevention: “Overweight and Obesity.” http://www.cdc.gov/nccdphp/dnpa/obesity/. Accessed 12/22/05.
(4) American Obesity Association. “Obesity in Minority Populations.” http://www.obesity.org/subs/fastfacts/Obesity_Minority_Pop.shtml. Accessed 8.01.05.
(5) Centers for Disease Control and Prevention. “Overweight and Obesity: Contributing Factors.” http://www.cdc.gov/nccdphp/dnpa/obesity/contributing_factors.htm. Accessed 12/22/05.
(6)Hauptman J, Lucas C, Baldrin MN, Collins H, Segal K. “Orlistat in the long-term treatment of obesity in primary care settings.” Archives of Family Medicine 9:160-167.
(7) NIH, NHLBI. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. HHS, PHS; 1998. p. 29-41.
|
CONTACT
GSK Inquiries
US Media inquiries
Brian Jones
(215) 751 3415
Brian.L.Jones@gsk.com
or
Malesia Dunn
(412) 200 3544
malesia.a.dunn@gsk.com
or
Patricia Seif
(215) 751 7709
or
Frank Murdolo
US Analyst
(215) 751 7002
or
Investor inquiries
Tom Curry
(215) 751 5419
or
UK Media inquiries
Philip Thomson
(020) 8047 5502
or
Gwenan White
(020) 8047 5502
or
Alice Hunt
(020) 8047 5502
or
European Analyst
Anita Kidgell
(020) 8047 5542
or
Investor inquiries
Sally Ferguson
(020) 8047 5543
or
David Mawdsley
(020) 8047 5564
|
|
